Authors


Elizabeth H. McEntire

Latest:

Good Samaritan Laws Aim to Encourage Assistance

But in real-world situations, such as when a bystander administers naloxone, there are gray areas.


Amber Chamberlain, PharmD Candidate

Latest:

Baby Steps to a Healthier You: Prioritizing Lifestyle Changes Over Medication

Take these 4 steps to help prevent health conditions and disease naturally.


Cara Rotatori, PharmD Candidate

Latest:

May 2021 Interactives: Case Studies

How should pharmacists help these patients?


Jessica Cho

Latest:

Updates on 2022 Changes to the American Diabetes Association Standards of Care

Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.


Claudia Martinez, PharmD Candidate

Latest:

Changing the Game: Pharmacy Students' Perspective on Naloxone OTC Approval

To eliminate the existing stigma in the community, addiction must be recognized as a treatable condition rather than an immoral act.


Robert L. Coleman, MD

Latest:

Lung Cancer Study Brings Pharmacists to the Forefront of Patient Care

Pharmacists have always been a vital member of the cancer care team, but the emergence of many new oral therapies is making their role in patient care a more prominent one.


Erin Gadhavi

Latest:

How Specialty Pharmacies Can Increase Access Through Patient Financing

It’s essential that health care providers across the patient journey demystify the costs of treatment and provide solutions to overcome the financial barriers.


Mary Beth Dameron, PharmD, BCACP

Latest:

Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer Disease

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.


James A. McKinnell, MD

Latest:

Looking Toward the Future of CDI Management

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.


Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Latest:

Breaking the Bank: Financial Toxicity in Cancer Care

The increasing economic burden of treatment may impact patient outcomes.


Krupal Ray

Latest:

GOLD Guidelines Provide Recommendations on Managing COPD

Pivotal resource helps health care professionals diagnose, manage, and prevent this group of lung diseases.


Victoria Russell, PharmD

Latest:

Clinical Overview: Treatment Recommendations for Pneumococcal Disease

Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.


Britny Brown, PharmD, BCOP

Latest:

Key Takeaways on mBC and eBC

Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes.


Maria A. Pino, PhD, MS, RPh

Latest:

Considerations for RSV Prevention in Special Patient Populations

Older adults, patients with weakened immune systems, individuals living in long-term facilities, and those with underlying cardiopulmonary disease are at a higher risk of developing severe RSV infection outcomes.


Sirena Kalinski, CPhT

Latest:

Point-of-Care Testing Offers New Opportunities for Pharmacy Technicians

Becoming experts in medical billing for point-of-care testing offers a new avenue for technicians to excel and show their value.


Nicole McMullen, PharmD, BCOP

Latest:

Revolutionizing Outpatient Oncology Care: The Seamless Integration of Artificial Intelligence

Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.


Diana Cirstea, MD

Latest:

Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma

Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.


Elaine Strauss, PharmD, MS, BCSCP

Latest:

Proper Use of Automation in Hazardous Drug Compounding Pharmacies

Although robotics can be instrumental in assuring sterility and reducing the overall number of potential hazardous drug exposure events, certain tasks require vigilant oversight.


Matthew M. Lei, PharmD, BCOP

Latest:

Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical Considerations

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.


Molly C. Gombos, PharmD, MPBA

Latest:

Specialty Drug Commercialization Process and Considerations

As specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.


Stephanie Trexler, PharmD, BCOP

Latest:

Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate Cancer

The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.



Ashley Walsh, PharmD

Latest:

Making “Rheum” for Biosimilars: Overcoming Reluctance

Despite the proven efficacy of biosimilars, both patients and health care providers often have some reluctance when switching from an originator drug to a biosimilar.


Maria Luoni

Latest:

Can Flexibility Fix Pharmacies? The Case for Contingent Workers

It’s time for pharmacies to take a page out of the books of hospitals and tech companies by expanding and streamlining their use of contingent labor.


Shelby Smoak, PhD

Latest:

Patient Navigation in the Specialty Pharmacy Space

Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.


Stephanie Pilat, PharmD

Latest:

What’s Ahead in the Adalimumab Biosimilar Pipeline in Dermatology

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.


Pam Forster

Latest:

You Previously Qualified for a Small Dispenser DSCSA Exemption. Now What?

As welcome as this compliance extension may be for those who qualify, it is critical they understand both their current and future regulatory obligations.


Daniel Abdullah, PharmD candidate

Latest:

Semaglutide Carries Potential Risk of Worsening Diabetic Retinopathy

Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.


Sabrina Bahadori, PharmD Candidate

Latest:

Bexagliflozin (Brenzavvy): Advancing Diabetes Management With SGLT-2 Inhibition

Beyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.


Christine Barrett, PharmD, BCOP

Latest:

The Role of Neoadjuvant Immunotherapy Advances in Resectable Stage III Melanoma

NADINA trial results support a new standard of care for these patients.